QualityStocks would like to highlight BrainStorm Cell Therapeutics (
OTCQB: BCLI), a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
In the company’s news,
BrainStorm Cell Therapeutics reports that it will initiate a pre-clinical study for multiple sclerosis (MS) at the Hebrew University Hadassah Medical Center’s SPF-grade animal laboratory in Jerusalem.
Based on favorable pre-clinical data published by BrainStorm chief scientist Professor Daniel Offen of Tel Aviv University, the company says it will conduct additional studies using the Experimental Autoimmune Encephalomyelitis (EAE) animal model to evaluate MS as an additional indication for its NurOwn™ technology.
NurOwn induces bone marrow-derived mesenchymal stem cells (MSC) to secrete high levels of neurotrophic factors to protect existing motor neurons, promotion of motor neuron growth, and re-establish nerve-muscle interaction.
Professor Dimitrios Karussis and Dr. Ibrahim Kassis, who have published extensively on pre-clinical research using the EAE model, will be the principal investigators of BrainStorm’s upcoming study.
The study was approved by the Institutional Animal Care and Use Committee (IACUC) of the Hebrew University.
Professor Karussis, a key opinion leader in the field of MS, is head of the multi-disciplinary MS Clinic and Center at Hadassah, member of the European Steering Committee for Bone Marrow Transplantation in MS, and a member of the Executive Board and Scientific Committee of the European School of Neuroimmunology (ESNI). He is also former board member of the European Council and Committee for Treatment and Research in MS, and has been the principal investigator of several multi-national clinical trials in MS conducted by global pharmaceutical companies.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit
www.QualityStocks.com
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
###
